Rethinking Ribociclib Dosage and Use in the Era of Patient-Centered Oncology-When Less Is More

Affiliations

Rina Yadav et al. JAMA Oncol. 2025.

. 2025 Nov 1;11(11):1285-1286.

doi: 10.1001/jamaoncol.2025.3549.

¹ Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis.

No abstract available

Comment in

600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.
Cardoso F, Jacot W, Kuemmel S, Gupta S, Cruz F, Balaraman R, Ferreira A, Ahola T, Chapko Y, Zhukova L, Chiang W, Li Z, Ji Y, Kaakiou N, Bolotova N, Sparano JA. Cardoso F, et al. JAMA Oncol. 2025 Nov 1;11(11):1356-1363. doi: 10.1001/jamaoncol.2025.3687. JAMA Oncol. 2025. PMID: 40996770 Free PMC article. Clinical Trial.
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch M, Moroose R, Visco F, Hortobagyi GN, Slamon DJ, Fresco R, Zarate JP, Li Z, Waters S, Hurvitz SA. Fasching PA, et al. JAMA Oncol. 2025 Nov 1;11(11):1364-1372. doi: 10.1001/jamaoncol.2025.3700. JAMA Oncol. 2025. PMID: 40996773 Free PMC article. Clinical Trial.